Therapeutic RNA-silencing oligonucleotides in metabolic diseases

No abstract is available for this paper.

• Publication year

  2022

• Venue

  Nature reviews. Drug discovery

• Publication date

  2022-02-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41573-022-00407-5PMID 35210608
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expanding the Reach of RNAi Therapeutics with Next Generation Lipophilic siRNA Conjugates

  2021cited by this paper
• Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity

  2021cited by this paper
• A genome-first approach to mortality and metabolic phenotypes in MTARC1 p.Ala165Thr (rs2642438) heterozygotes and homozygotes.

  2021cited by this paper
• Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides

  2021cited by this paper
• Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System

  2021cited by this paper
• Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran

  2021cited by this paper
• Fructose and fructose kinase in cancer and other pathologies.

  2021cited by this paper
• An oral antisense oligonucleotide for PCSK9 inhibition

  2021cited by this paper
• Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1

  2021cited by this paper
• Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

  2021cited by this paper
• Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction

  2021cited by this paper
• Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort

  2021cited by this paper
• SAFETY, PHARMACODYNAMICS, AND BLOOD PRESSURE EFFECTS OF ALN-AGT, AN RNA INTERFERENCE THERAPEUTIC TARGETING ANGIOTENSINOGEN, IN A RANDOMIZED SINGLE ASCENDING DOSE STUDY OF HYPERTENSIVE ADULTS

  2021cited by this paper
• Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx

  2021cited by this paper
• Inclisiran: First Approval

  2021cited by this paper
• EFFECT OF IONIS-AGT-LRX, AN ANTISENSE INHIBITOR OF ANGIOTENSINOGEN PRODUCTION, IN HEALTHY VOLUNTEERS AND IN SUBJECTS WITH HYPERTENSION: RESULTS OF PHASE 1 AND PHASE 2 STUDIES

  2021cited by this paper
• Dual Glycolate Oxidase/Lactate Dehydrogenase A Inhibitors for Primary Hyperoxaluria.

  2021cited by this paper
• The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery

  2021cited by this paper
• Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.

  2021cited by this paper
• RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia

  2020cited by this paper
• Hyperhomocysteinemia in patients with acute porphyrias: A potentially dangerous metabolic crossroad?

  2020cited by this paper
• Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy.

  2020cited by this paper
• Fructose Production and Metabolism in the Kidney.

  2020cited by this paper
• Givosiran: First Approval

  2020cited by this paper
• Mechanism of Action

  2020cited by this paper
• Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

  2020cited by this paper
• Specific ablation of the NCoR corepressor δ splice variant reveals alternative RNA splicing as a key regulator of hepatic metabolism

  2020cited by this paper
• Evinacumab in Patients with Refractory Hypercholesterolemia.

  2020cited by this paper
• Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort.

  2020cited by this paper
• RNA Interference Targeting Liver Angiopoietin-Like Protein 3 Protects from Nephrotic Syndrome in a Rat Model Via Amelioration of Pathologic Hypertriglyceridemia

  2020cited by this paper
• Genome‐wide Association Study and Meta‐analysis on Alcohol‐Associated Liver Cirrhosis Identifies Genetic Risk Factors

  2020cited by this paper
• HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.

  2020cited by this paper
• Regulation of lipoprotein lipase-mediated lipolysis of triglycerides.

  2020cited by this paper
• Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates

  2020cited by this paper
• LDL-Cholesterol Reduction by ANGPTL3 Inhibition in Mice Is Dependent on Endothelial Lipase.

  2020cited by this paper
• Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease.

  2020cited by this paper
• Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.

  2020cited by this paper
• Toxicological profile of lipid-based nanostructures: are they considered as completely safe nanocarriers?

  2020cited by this paper
• Recent advances in siRNA delivery mediated by lipid-based nanoparticles

  2020cited by this paper
• Therapeutic approaches in the treatment of gout.

  2020cited by this paper
• Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance

  2020cited by this paper
• Evinacumab for Homozygous Familial Hypercholesterolemia.

  2020cited by this paper
• Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.

  2020cited by this paper
• Lipoprotein(a) plasma levels are not associated with survival after acute coronary syndromes: An observational cohort study

  2020cited by this paper
• Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.

  2020cited by this paper
• Abstract 15751: Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiopoietin-like Protein 3, in Patients With Hypercholesterolemia

  2020cited by this paper
• Insights into genetic variants associated with NASH-fibrosis from metabolite profiling

  2020cited by this paper
• Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria

  2020cited by this paper
• Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.

  2020cited by this paper
• An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins

  2020cited by this paper
• Advances in oligonucleotide drug delivery

  2020cited by this paper
• PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis

  2020cited by this paper
• Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.

  2020cited by this paper
• Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.

  2020cited by this paper
• Lipoprotein(a) concentration is associated with risk of type 2 diabetes and cardiovascular events in a Chinese population with very high cardiovascular risk

  2020cited by this paper
• Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.

  2020cited by this paper
• Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.

  2020cited by this paper
• Exome-wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated with Fatty Liver Disease.

  2020cited by this paper
• Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease.

  2020cited by this paper
• Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.

  2019cited by this paper
• Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria

  2019cited by this paper
• Glucagon Receptor Signaling and Glucagon Resistance

  2019cited by this paper
• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2019cited by this paper
• A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease

  2019cited by this paper
• Clinical review on triglycerides

  2019cited by this paper
• Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index

  2019cited by this paper
• Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads.

  2019cited by this paper
• Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia

  2019cited by this paper
• Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids.

  2019cited by this paper
• Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis

  2019cited by this paper
• Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity

  2019cited by this paper
• Clinical outcome after lipectomy in the management of patients with human immunodeficiency virus-associated dorsocervical fat accumulation

  2019cited by this paper
• Gain-of-Function Mutations of SLC16A11 Contribute to the Pathogenesis of Type 2 Diabetes.

  2019cited by this paper
• Selective tissue targeting of synthetic nucleic acid drugs.

  2019cited by this paper
• Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.

  2019cited by this paper
• Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial

  2019cited by this paper
• Genetics of Common, Complex Coronary Artery Disease.

  2019cited by this paper
• Genome-wide association study of plasma lipids

  2019cited by this paper
• Re-Engineering RNA Molecules into Therapeutic Agents.

  2019cited by this paper
• Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes

  2019cited by this paper
• Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism

  2019cited by this paper
• 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

  2019cited by this paper
• Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice

  2019cited by this paper
• A NEW DAWN FOR MANAGING DYSLIPIDEMIAS: THE ERA OF RNA-BASED THERAPIES.

  2019cited by this paper
• A siRNA mediated hepatic dpp4 knockdown affects lipid, but not glucose metabolism in diabetic mice

  2019cited by this paper
• Role of LDL apheresis in a case of homozygous familial hypercholesterolemia.

  2019cited by this paper
• Role of HSD17B13 in the liver physiology and pathophysiology.

  2019cited by this paper
• The current state and future directions of RNAi-based therapeutics

  2019cited by this paper
• The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

  2019cited by this paper
• Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

  2019cited by this paper
• Volanesorsen, Familial Chylomicronemia Syndrome, and Thrombocytopenia. Reply.

  2019cited by this paper
• PNPLA3, CGI‐58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice

  2019cited by this paper
• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

  2019cited by this paper
• Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy

  2019cited by this paper
• Familial Hypercholesterolemia

  2019cited by this paper
• Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.

  2018cited by this paper
• Novel therapeutic approaches in primary hyperoxaluria

  2018cited by this paper
• DGAT2 Inhibition Alters Aspects of Triglyceride Metabolism in Rodents but Not in Non-human Primates.

  2018cited by this paper
• Improving siRNA Delivery In Vivo Through Lipid Conjugation

  2018cited by this paper
• Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate.

  2018cited by this paper

• Nucleic-Acid-Based Strategies and Nanotechnology Applications for Targeted Therapy.

  2026cites this paper
• Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management

  2026cites this paper
• Real-Time Process Monitoring Ammonolysis of Oligonucleotides with Online FTIR Spectroscopy

  2026cites this paper
• RNA-based drugs: current, imminent and possible therapeutic applications.

  2025cites this paper
• Assembly-Driven Chemistry of Magnetic Nanoparticles: From Structural Design to Biomedical Applications.

  2025cites this paper
• Exosomal non-coding RNAs: mediators of crosstalk between cancer and cancer stem cells

  2025cites this paper
• Downregulation of the mitochondrial tRNA-derived fragment mt-tRF-LeuTAA enhances skeletal muscle insulin sensitivity.

  2025cites this paper
• The RNA revolution in medicine: from gene regulation to clinical therapeutics

  2025cites this paper
• RNA chemistry and therapeutics

  2025cites this paper
• Hepatic IκBζ Promotes Alcohol-Associated Liver Disease and Acute Hepatitis by Enhancing CXCL1-Mediated Neutrophil Infiltration.

  2025cites this paper
• Perspectives in Amyotrophic Lateral Sclerosis: Biomarkers, Omics, and Gene Therapy Informing Disease and Treatment

  2025cites this paper
• Stereochemistry of Phosphorothioate Linkages Impacts the Structure and Binding Affinity of Aptamers and DNAzymes.

  2025cites this paper
• Effect of pH-Responsive Ligands on mRNA Knockdown in EGFR-Targeting Ligand-Conjugated siRNAs.

  2025cites this paper
• Targeting ion homeostasis in metabolic diseases: molecular mechanisms and targeted therapies.

  2025cites this paper
• Atom-engineered metabzymes for catalytic metabolic regulation-augmented immunotherapy

  2025cites this paper
• The Role of Micro-Ribonucleic Acid and Small Interfering-Ribonucleic Acid in Precision Nutrition for Obesity Management.

  2025cites this paper
• GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases

  2025cites this paper
• Advanced multifunctional nano-delivery platform focusing on treating diseases related to lipid metabolism via targeted intervention in various lipid metabolic processes

  2025cites this paper
• A Novel Pot-Economy Approach to the Synthesis of Triantennary GalNAc-Oligonucleotide

  2024cites this paper
• VLDL Biogenesis and Secretion: It Takes a Village

  2024cites this paper
• Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases

  2024cites this paper
• Chemically Modified Platforms for Better RNA Therapeutics.

  2024cites this paper
• MicroRNA therapeutic delivery strategies: A review

  2024cites this paper
• New insights of DsbA-L in the pathogenesis of metabolic diseases

  2024cites this paper
• Back to the Future of Metabolism—Advances in the Discovery and Characterization of Unknown Biocatalytic Functions and Pathways

  2024cites this paper
• Novel diamine-scaffold based N-acetylgalactosamine (GalNAc)–siRNA conjugate: synthesis and in vivo activities

  2024cites this paper
• RNase H-sensitive multifunctional ASO-based constructs as promising tools for the treatment of multifactorial complex pathologies.

  2024cites this paper
• Fasting-induced miR-7a-5p in AgRP neurons regulates food intake.

  2024cites this paper
• An artificial metabzyme for tumour-cell-specific metabolic therapy

  2024cites this paper
• The role of structure in regulatory RNA elements

  2024cites this paper
• 基于非靶向代谢组学探索辐射诱导的小鼠肺上皮细胞代谢改变

  2024cites this paper
• DNA nanotechnology-based strategies for minimising hybridisation-dependent off-target effects in oligonucleotide therapies.

  2024cites this paper
• Lumasiran for primary hyperoxaluria type 1: What we have learned?

  2023cites this paper
• Novel roles of PIWI proteins and PIWI-interacting RNAs in human health and diseases

  2023cites this paper
• Transfer RNA and ribosomal RNA fragments - emerging players in plant-microbe interactions.

  2023cites this paper
• Impact of Peptide Sequence on Functional siRNA Delivery and Gene Knockdown with Cyclic Amphipathic Peptide Delivery Agents

  2023cites this paper
• Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges

  2023cites this paper
• Small‐molecule drugs as RNA‐targeted degraders

  2023cites this paper
• IGF2BPs as novel m6A readers: Diverse roles in regulating cancer cell biological functions, hypoxia adaptation, metabolism, and immunosuppressive tumor microenvironment

  2023cites this paper
• Total stepwise solid-phase synthesis of peptide-oligonucleotide conjugates using side-chain Boc/tBu protecting groups.

  2023cites this paper
• Aptamer-Based Targeted Delivery of Functional Nucleic Acids.

  2023cites this paper
• The effect of G0S2 on insulin sensitivity: A proteomic analysis in a G0S2-overexpressed high-fat diet mouse model

  2023cites this paper
• Aptamer-Based Targeted Protein Degradation.

  2023cites this paper
• From Single- to Multi-organ-on-a-Chip System for Studying Metabolic Diseases

  2023cites this paper
• Molecular elements: novel approaches for molecular building

  2023cites this paper
• Exosomal ncRNAs facilitate interactive 'dialogue' between tumor cells and tumor-associated macrophages.

  2022cites this paper
• Amide Modifications in the Seed Region of the Guide Strand Improve the On-Target Specificity of Short Interfering RNA.

  2022cites this paper
• Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD

  2022cites this paper
• Derivatization with fatty acids in peptide and protein drug discovery

  2022cites this paper